Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
Background: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621925000018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087383333404672 |
|---|---|
| author | Jialin Qian Tianqing Chu |
| author_facet | Jialin Qian Tianqing Chu |
| author_sort | Jialin Qian |
| collection | DOAJ |
| description | Background: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance. Case description: A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled. Conclusions: Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients. |
| format | Article |
| id | doaj-art-7abf889f62514feea7e8c5398ba4170a |
| institution | Kabale University |
| issn | 2666-6219 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Problems in Cancer: Case Reports |
| spelling | doaj-art-7abf889f62514feea7e8c5398ba4170a2025-02-06T05:12:53ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192025-03-0117100349Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case reportJialin Qian0Tianqing Chu1Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR ChinaCorresponding author.; Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR ChinaBackground: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance. Case description: A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled. Conclusions: Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.http://www.sciencedirect.com/science/article/pii/S2666621925000018ALK-positiveNon-small cell lung cancerCase reportLorlatinibTyrosine kinase inhibitors (TKI) |
| spellingShingle | Jialin Qian Tianqing Chu Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report Current Problems in Cancer: Case Reports ALK-positive Non-small cell lung cancer Case report Lorlatinib Tyrosine kinase inhibitors (TKI) |
| title | Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report |
| title_full | Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report |
| title_fullStr | Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report |
| title_full_unstemmed | Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report |
| title_short | Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report |
| title_sort | long term efficacy and safety of lorlatinib in alk positive non small cell lung cancer a case report |
| topic | ALK-positive Non-small cell lung cancer Case report Lorlatinib Tyrosine kinase inhibitors (TKI) |
| url | http://www.sciencedirect.com/science/article/pii/S2666621925000018 |
| work_keys_str_mv | AT jialinqian longtermefficacyandsafetyoflorlatinibinalkpositivenonsmallcelllungcanceracasereport AT tianqingchu longtermefficacyandsafetyoflorlatinibinalkpositivenonsmallcelllungcanceracasereport |